1-(1-acetylpiperidin-4-yl)-3-(2-methylbenzo[d]thiazol-6-yl)urea | 1056674-17-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 1-(1-acetylpiperidin-4-yl)-3-(2-methylbenzo[d]thiazol-6-yl)urea
• 英文别名: 1-(1-Acetylpiperidin-4-yl)-3-(2-methyl-1,3-benzothiazol-6-yl)urea
• CAS: 1056674-17-9
• 化学式: C₁₆H₂₀N₄O₂S
• 分子量: 332.426
• InChiKey: ORLCOVFNJBPJLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• SOLUBLE EPOXIDE HYDROLASE INHIBITORS
  申请人：Gless Richard D.

  公开号：US20080227780A1

  公开（公告）日：2008-09-18

  Disclosed are urea compounds, stereoisomer, or pharmaceutical acceptable salt thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.

  本公开涉及尿素化合物、其立体异构体或药用可接受的盐，以及抑制可溶性环氧化物水解酶（sEH）的组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物治疗患者的方法。这些化合物、组合物和方法可用于治疗多种由sEH介导的疾病，包括高血压、心血管、炎症、肺部和糖尿病相关疾病。
• 4-PIPERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
  申请人：Arete Therapeutics, Inc.

  公开号：EP2132176A1

  公开（公告）日：2009-12-16
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
  申请人：Aavula Bhasker R.

  公开号：US20090247521A1

  公开（公告）日：2009-10-01

  The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.
• [EN] 4 -PI PERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ÉPOXYDE HYDROLASE SOLUBLE
  申请人：ARETE THERAPEUTICS INC

  公开号：WO2008112022A1

  公开（公告）日：2008-09-18

  [EN] Disclosed are urea compounds, stereoisomer, or pharmaceutical acceptable salt thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.
  [FR] L'invention concerne des composés d'urée, des stéréo-isomères, ou un sel pharmaceutiquement acceptable de ceux-ci, et des compositions qui inhibent l'époxyde hydrolase soluble (sEH), des méthodes de préparation de ces composés et compositions, ainsi que des méthodes de traitement de patients utilisant ces composés et compositions. Les composés, compositions et méthodes de cette invention permettent de traiter diverses maladies induites par l'époxyde hydrolase soluble, y compris des maladies hypertensives, cardiovasculaires, inflammatoires, pulmonaires et associées au diabète.
• [EN] SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION<br/>[FR] INHIBITEURS SOLUBLES DE L'ÉPOXYDE HYDROLASE POUR LE TRAITEMENT DE DYSFONCTIONNEMENT ENDOTHÉLIAL
  申请人：ARETE THERAPEUTICS INC

  公开号：WO2009086426A2

  公开（公告）日：2009-07-09

  The present invention generally relates to a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for use in treating and ameliorating the symptoms of diseases related to endothelial dysfunction.